References
33. Idenix Pharmaceuticals Reports Sustained Virologic Response
Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir
(IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and
Simeprevir. Idenix Pharmaceuticals 2014 January 13;Available at: URL:
http://ir.idenix.com/releasedetail.cfm?ReleaseID=818775. Accessed
February 17, 2014.
34. (34) Flisiak R, Feinman SV, Jablkowski M et al. The cyclophilin
inhibitor Debio 025 combined with PEG IFNalpha2a significantly
reduces viral load in treatment-naive hepatitis C patients. Hepatology
2009;49(5):1460-1468.
35. Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection
by targeting microRNA. N Engl J Med 2013;368(18):1685-1694.
36. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old
family. J Interferon Cytokine Res 2010;30(8):555-564.
32